Victrex

China Plant And Magma Programme Will Expand Market Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

12 May 25

Updated

26 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-33.1%

10.0%

-33.1%

10.0%

You can edit this narrative until Nov 27 2:10 PM. Then, changes will post as Updates.

Author's Valuation

UK£8.0116.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 26 Nov 25

Fair value Decreased 1.28%

VCT: Future Recovery Will Be Driven By Medical Volume Rebound

Victrex's analyst price targets have been revised downward, with a notable reduction from previous estimates such as 1,100 GBp to 940 GBp. Analysts cite ongoing caution towards the European chemicals sector and softer expectations for the company's recovery. Analyst Commentary Recent analyst assessments reflect a shift in sentiment towards Victrex's near-term performance and sector positioning.

Shared on 11 Nov 25

Fair value Decreased 7.51%

VCT: Future Leadership Transition Will Guide Recovery As Margins Improve

Analysts have reduced their price targets for Victrex, with consensus moving from approximately £8.77 to £8.11 per share. This reflects concerns about weaker profit margins and slower growth forecasts in the chemicals sector.

AnalystConsensusTarget Fair Value

UK£8.01

16.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.78%

Chemicals revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.73%

Calculation

UK£56.92m

Earnings '28

15.13x

PE Ratio '28

UK£861.10m

Market Cap '28

UK£861.10m

Market Cap '28

86.99m

No. shares '28

UK£9.90

Share Price '28

UK£9.90 Share Price '28

Discounted to 2025 @ 7.74% p.a.

UK£7.91

Fair Value '25